Not Yet RecruitingNot Applicable

Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety

60 participantsStarted 2026-06-15

Plain-language summary

This study aims to evaluate the efficacy and safety of Leonurus cardiaca extract in reducing anxiety symptoms in adults with Generalized Anxiety Disorder (GAD). Sixty drug-free participants aged 20-50 years with a diagnosis of GAD will be randomly assigned to receive either Leonurus cardiaca extract or placebo for 30 days. The primary outcome is the reduction in anxiety symptoms assessed by the SCAG scale. Secondary outcomes include changes in quality of life (SF-12), perceived stress (PSQ), anxiety severity (HAM-A), and anthropometric measures. Safety will be assessed through liver, kidney, and thyroid function tests. Assessments will be conducted at baseline, day 14, and day 30.

Who can participate

Age range20 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 20 to 50 years * Diagnosis of a generalised anxiety disorder (GAD), with manifestations occurring for \>= 6 months that include excessive worry, poor concentration, restlessness, muscle tension, irritability, fatigue and difficulty sleeping Exclusion Criteria: * Women who are pregnant or breastfeeding * Use of hormonal contraceptives in the last 3 months * Current diagnosis of major psychiatric disorders (e.g., major depressive disorder, severe anxiety disorders, schizophrenia, bipolar disorder) * Known endocrine disorders (e.g., hypothyroidism, hyperthyroidism, diabetes) * Use of medications that could affect mood or the menstrual cycle (e.g., SSRIs, anxiolytics, antipsychotics) * Severe hepatic or renal impairment * Any other serious or unstable medical condition that, in the investigator's judgment, could interfere with study participation

What they're measuring

Change in SCAG (Sandoz Clinical Assessment-Geriatric) score

Timeframe: Baseline, week 1 and week 4

Trial details

NCT IDNCT06954038

SponsorAzienda di Servizi alla Persona di Pavia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-15

Contact for this trial

Mariangela Rondanelli

+39 0382381749 mariangela.rondanelli@unipv.it